Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
November 03 2023 - 12:00PM
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage
biotechnology company whose proprietary INTASYL™ RNAi platform
technology is designed to make immune cells more effective in
killing tumor cells, today announced the presentation of new
preclinical data at the 38th Annual Meeting of the Society for
Immunotherapy of Cancer (SITC). The event is scheduled to take
place in San Diego, California, from November 1-5, 2023. Phio’s
innovative preclinical study data highlights the benefit of
intratumoral injection (IT) of an INTASYL compound targeting CTLA-4
(27790) in conjunction with systemic anti-PD-1 antibody therapy.
Preclinical studies have demonstrated:
- The combination of INTASYL compound 27790 with systemic
anti-PD-1 antibody therapy significantly enhanced the efficacy of
anti-PD-1 mAb therapy in vivo.
- The combination of INTASYL compound 27790 and anti-PD-1
elicited complete regression of ~40% of IT treated tumors in a
mouse model.
- Additionally, INTASYL compound 27790 appeared to improve the
efficacy of anti-PD-1 therapy toward those tumors not treated
directly with 27790.
- INTASYL compound 27790 increased the percentage of reactive
CD8+ T cells in the tumor while decreasing
immunosuppressive/pro-tumor macrophages in the treated tumor
micro-environment.
“These data underscore the potential of Phio’s INTASYL™ RNAi
platform technology to offer a strategy to enhance the
effectiveness of immune checkpoint inhibition therapies,” said
Phio’s President & CEO Robert Bitterman, “and further
demonstrate the flexibility and capabilities of the INTASYL
platform.”
Presentation Details are as follows:
Title: |
Intratumoral CTLA-4-targeting INTASYL™ self-delivering RNAi
enhances tumor control in combination with systemic anti-PD-1
antibody therapy in vivo suggesting a strategy to mitigate
irSAEs |
Presenting Author: |
Melissa Maxwell |
Date and Time: |
9:00 am - 8:30 pm PST on Saturday, November 4, 2023 |
Location: |
Exhibit Halls A and B1 – San Diego Convention Center |
The poster presentation will be accessible in person and will also
be made available on the "Investors – Events and Presentations"
section of the Company's website (click here). |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage
biotechnology company whose proprietary INTASYL™ RNAi technology is
designed to make immune cells more effective in killing tumor
cells. INTASYL is the only self-delivering RNAi technology focused
on immuno-oncology therapeutics. INTASYL drugs precisely target
specific proteins that reduce the body’s ability to fight cancer,
without the need for specialized formulations or drug delivery
systems.
For additional information, visit the Company’s website,
www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as
"intends," "believes," "anticipates," "indicates," "plans,"
"expects," "suggests," "may," "would," "should," "potential,"
"designed to," "will," "ongoing," "estimate," "forecast," "target,"
"predict," "could" and similar references, although not all
forward-looking statements contain these words. These statements
are based only on our current beliefs, expectations and assumptions
and are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are
outside of our control. Examples of forward-looking statements
include statements regarding the combination of an INTASYL compound
targeting CTLA-4 and a systemic anti-PD-1 antibody to demonstrate
enhanced tumor control. Our actual results may differ materially
from those indicated in the forward-looking statements as a result
of a number of important factors, including, but not limited to,
the impact to our business and operations by inflationary
pressures, rising interest rates, recession fears, the development
of our product candidates, results from our preclinical and
clinical activities, our ability to execute on business strategies,
our ability to develop our product candidates with collaboration
partners, and the success of any such collaborations, the timeline
and duration for advancing our product candidates into clinical
development, the timing or likelihood of regulatory filings and
approvals, the success of our efforts to commercialize our product
candidates if approved, our ability to manufacture and supply our
product candidates for clinical activities, and for commercial use
if approved, the scope of protection we are able to establish and
maintain for intellectual property rights covering our technology
platform, our ability to obtain future financing, market and other
conditions and those identified in our Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q under the caption
"Risk Factors" and in other filings the Company periodically makes
with the SEC. Readers are urged to review these risk factors and to
not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. Phio does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release, except as
required by law.
Contact:Phio Pharmaceuticals
Corp.ir@phiopharma.com
PR ContactMichael AdamsBridge View
Mediaadams@bridgeviewmedia.com
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Aug 2023 to Aug 2024